The startup company Vesigen will develop and commercialize the drug-delivery technology created in the lab of Harvard Chan School Professor Quan Lu.
Tags: science-technology harvard-th-chan-school-of-public-health office-of-technology-development quan-lu caroline-perry armms arrdc1-mediated-microvesicles blavatnik-biomedical-accesserator large-molecule-drugs vesigen-therapeutics
New formulations enable oral delivery of therapeutics traditionally delivered intravenously.
Tags: engineering basic-research health-medicine office-of-technology-development i20-therapeutics
Aldatu Biosciences, a company born in Harvard’s labs and nurtured in its entrepreneurial ecosystem, helps the region ramp up COVID-19 testing.
Tags: covid-19 coronavirus harvard-medical-school health-medicine alvin-powell office-of-technology-development max-essex beth-israel-deaconess-medical-center aldatu-biosciences christopher-rowley david-raiser grant-zimmerman i-lab iain-macleod isaac-kohlberg jeffrey-saffitz pagliuca-harvard-life-lab pandaa
Harvard stem-cell research receives support from Sarepta Therapeutics for work on Duchenne muscular dystrophy.
Tags: science-technology stem-cells office-of-technology-development amy-wagers caroline-perry duchenne-muscular-dystrophy sarepta-therapeutics
Harvard professors David Ginty and Lauren Orefice describe how their innovations present a novel approach to treating tactile hypersensitivity in patients with autism-spectrum disorders.
Tags: science-technology autism basic-research office-of-technology-development david-ginty lauren-orefice tactile-hypersensitivity
Chemists at Harvard and Eisai, a Japanese pharmaceutical company, have synthesized halichondrin, a potent anti-cancer agent found naturally in sea sponges. Because of the molecule’s “fiendishly complex” design, the feat took three decades.
Tags: health-medicine office-of-technology-development anti-cancer eisai halichondrin sea-sponge takashi-owa yoshito-kishi
Developed through Harvard’s Blavatnik Biomedical Accelerator, an innovative immune-silent stem cell technology could lead to novel cell therapies to treat “any patient with any disease.”
Tags: science-technology office-of-technology-development blavatnik-biomedical-accelerator biotech chad-cowan department-of-stem-cell-and-regenerative-biology isaac-t-kohlberg otd richard-mulligan sana-biotechnology steve-harr vivian-berlin
A half-day conference at Harvard Business School examined the growing promise of research on aging and the potential of now-experimental interventions to one day ease the burdens of infirmity.
Tags: harvard-medical-school health-medicine alvin-powell harvard-th-chan-school-of-public-health aging caremore-health george-church harvard-business-school national-institute-on-aging office-of-technology-development richard-hodes sachin-jain
Page 1 of 1